Nimotuzumab clinical trials
Nimotuzumab is named as an intervention in 34 current clinical trials in our China register. 19 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sun Yat-sen University (5). The most-studied condition is Head & Neck Cancer.
Where Nimotuzumab is approved
All regulators →- 1 EU orphan designation, most recently for treatment of pancreatic cancer (3 Jun 2008, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Nimotuzumab works
All drug targets →- Epidermal growth factor receptor erbB1 inhibitor InhibitorTarget: EGFR epidermal growth factor receptorChEMBL only
- CancerPhase 3
- Cervical cancerPhase 3
- Cervical squamous cell carcinomaPhase 3
- Colorectal cancerPhase 3
- Diffuse intrinsic pontine gliomaPhase 3
- Esophageal cancerPhase 3
- Esophageal squamous cell carcinomaPhase 3
- Exocrine pancreatic carcinomaPhase 3
- Gastric adenocarcinomaPhase 3
- Gastric cancerPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2108359, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7988, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Nimotuzumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Nimotuzumab
34 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Nimotuzumab
34 conditionsAll 34 conditions
| Condition (as registered) | Trials |
|---|---|
| Head & Neck Cancer | 5 |
| Nasopharyngeal Carcinoma | 4 |
| Nasopharyngeal Carcinoma by AJCC V8 Stage | 2 |
| Esophageal Squamous Cell Carcinoma | 2 |
| Esophageal Cancer | 2 |
| Chemoradiation | 2 |
| Head & Neck Squamous Cell Carcinoma | 2 |
| Head and Neck Squamous Cell Carcinoma | 2 |
| Pancreatic Cancer | 2 |
| Pancreatic Cancer Resectable | 1 |
| Pancreatic Neuroendocrine Neoplasm | 1 |
| Radiotherapy | 1 |
| Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | 1 |
| Nasopharyngeal Carcinoma (NPC) | 1 |
| Resectable Esophageal Squamous Cell Carcinoma | 1 |
| Esophagus Cancer | 1 |
| Esophagogastric Junction Cancer | 1 |
| Targeted Therapy | 1 |
| Pancreatic Cancer Non-resectable | 1 |
| Pancreatic Ductal Adenocarcinoma (PDAC) | 1 |
| Recurrent or Metastatic Nasopharyngeal Carcinoma | 1 |
| Postoperative Adjuvant Treatment | 1 |
| Head and Neck Cancer | 1 |
| Chemotherapy Effect | 1 |
| Surgery | 1 |
| Locally Advanced Pancreatic Cancer | 1 |
| Uterine Cervical Neoplasms | 1 |
| Metastatic Pancreatic Carcinoma | 1 |
| Borderline Resectable Pancreatic Adenocarcinoma | 1 |
| RAS Mutations or Amplifications | 1 |
| Cervical Squamous Cell Carcinoma | 1 |
| Pancreatic Cancer, Adult | 1 |
| Head and Neck Squamous Cell Carcinoma (HNSCC) | 1 |
| Neoadjuvant Therapy | 1 |
Sponsors
lead sponsor per trial+ 6 more sponsors in the trial list above.
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 34 | 19 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Nimotuzumab trials
How many clinical trials are testing Nimotuzumab?
34 current trials in our China register name Nimotuzumab (also registered as H-R3) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Nimotuzumab trials recruiting patients?
Yes. 19 of the 34 trials are recruiting: 19 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Nimotuzumab clinical trials?
Sun Yat-sen University (5), Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4), Fudan University (3) and Zhejiang University (3), among 21 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nimotuzumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nimotuzumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nimotuzumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.